This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Merck Frosst Canada Ltd.Better access for a treatment to help osteoporosis patients - Positive CDR recommendation and drug plan listing in Ontario for FOSAVANCE(R) 70/5600. Media Release: 17 Jun 2009. Available from: URL: http://www.merckfrosst.com
Rights and permissions
About this article
Cite this article
Patients with osteoporosis in Canada are set to get improved access to alendronic acid/colecalciferol. Pharmacoecon. Outcomes News 581, 10 (2009). https://doi.org/10.2165/00151234-200905810-00033
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200905810-00033